Abstract:Introduction The main finding of a large-scale collaborative study (Rees et al. Nat Neurosci 2020;23(2) 179-184), which focused on de novo mutations in schizophrenia, was the discovery of an enrichment of these mutations in the SLC6A1 gene. This gene encodes the gamma-aminobutyric acid (GABA) transporter GAT1, thereby encouraging further research into novel schizophrenia targets within the GABA pathway. However, the gene was not highlighted in recent schizophrenia genetic studies, while typically pathogenic SLC6A1 mutations result in epilepsy, motor dysfunction, autistic spectrum disorder (ASD) and developmental delay. The absence of genetic replication for SLC6A1's involvement in schizophrenia and the differing clinical spectrum for SLC6A1 mutations led us to study in depth one of the only three original probands from the Rees et al. 2020 study. Objectives In our comprehensive case study, we delved deep into the relationship between the SLC6A1 mutation and schizophrenia. Methods Our subject, a patient who first presented with acute mania symptoms at age 15 and was later diagnosed with schizophrenia, carried the SLC6A1 Arg211Cys mutation. Over a detailed 25-year follow-up, we conducted an array of assessments and tests, including cognitive testing, personality assessments, EEG, and 1H-MRS. Results Notably, we discovered abnormal GABA levels, potentially indicating a dysfunction in GABA reuptake, adding a new layer of complexity to our understanding. Further analysis revealed a significant correlation between the patient's clinical picture and a polygenic background, rather than the SLC6A1 mutation. Despite having a high polygenic risk score for bipolar disorder, the dominant features of his condition were more representative of schizophrenia. Interestingly, neither the patient nor his father, who also showed a higher BP PRS, had a diagnosis of bipolar disorder. The pathogenic significance of the mutation warrants investigation in cells of neuronal origin. We generated induced pluripotent stem cells (iPSC) from the patient and his parents. This approach provides us with a platform for future investigations into the pathogenic significance of the mutation in neuronal cells. The Human Pluripotent Stem Cell Registry accession numbers of those cells are MHRCCGi001-A (patient), MHRCCGi005-A (mother) and MHRCCGi004-A (father). Conclusions In the presented case the clinical picture is rather explained by the polygenic background than by the SLC6A1 Arg211Cys mutation. The study is supported by Russian Science Foundation, grant 21-15-00124 (https://rscf.ru/project/21-15-00124) Disclosure of Interest None Declared

Ultrarare Loss-of-Function Mutations in the Genes Encoding the Ionotropic Glutamate Receptors of Kainate Subtypes Associated with Schizophrenia Disrupt the Interaction with PSD95

KCNH2-3.1 Mediates Aberrant Complement Activation and Impaired Hippocampal-Medial Prefrontal Circuitry Associated with Working Memory Deficits.

Multiple Rare Risk Coding Variants in Postsynaptic Density-Related Genes Associated With Schizophrenia Susceptibility

The genetics of schizophrenia: glutamate not dopamine?

KCTD10 P.c124w Variant Contributes to Schizophrenia by Attenuating LLPS-mediated Synapse Formation.

Differential functional consequences of GRIN2A mutations associated with schizophrenia and neurodevelopmental disorders

Genetic Diversity in Schizophrenia: Developmental Implications of Ultra-Rare, Protein-Truncating Mutations

Delving into the significance of the His289Tyr single-nucleotide polymorphism in the glutamate ionotropic receptor kainate-1 (Grik1) gene of a genetically audiogenic seizure model

Identification of Rare Mutations of Two Presynaptic Cytomatrix Genes BSN and PCLO in Schizophrenia and Bipolar Disorder

A Primate-Specific, Brain Isoform of KCNH2 Affects Cortical Physiology, Cognition, Neuronal Repolarization and Risk of Schizophrenia

Glutamatergic dysfunction in Schizophrenia

Human mutations in SLITRK3 implicated in GABAergic synapse development in mice

Characterization of a Novel Mutation in SLC1A1 Associated with Schizophrenia

Clinical and functional consequences of GRIA variants in patients with neurological diseases

Mutations of schizophrenia risk gene SETD1A dysregulate synaptic function in human neurons

Modulation on Glutamic Pathway of Frontal-Striatum-Thalamus by Rs11146020 and Rs3813296 Gene Polymorphism in First-Episode Negative Schizophrenia

A Frameshift Variant of GluN2A Identified in an Epilepsy Patient Results in NMDA Receptor Mistargeting

Association of <i>NKAPL</i> rs1635 With Cognitive Function in Early-Onset Schizophrenia

The Role of 3' Regulatory Region Flanking Kinectin 1 Gene in Schizophrenia

Molecular Mechanisms of Epileptic Encephalopathy Caused by KCNMA1 Loss-of-Function Mutations

The SLC6A1 Mutation Schizophrenia case — A Comprehensive Case Study With iPSC Generation